Cargando…

A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer

BACKGROUND: While many of these agents have been compared in prospective clinical trials, the gemcitabine/platinumbased regimens have not been compared in a prospective, randomized clinical trial. While bothgemcitabine/carboplatin and gemcitabine/cisplatin have a similar ORR in separate clinical tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le, Tran N., Harvey, Rachel E., Kim, Christine K., Brown, Jubilee, Coleman, Robert L., Smith, Judith A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5684736/ https://www.ncbi.nlm.nih.gov/pubmed/29158911 http://dx.doi.org/10.1186/s40661-017-0053-x

Ejemplares similares

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer
por: Kawaguchi, Hiroshi, et al.
Publicado: (2014)

Complete surgical resection of isolated recurrent high-grade epithelial ovarian cancer in highly selected patients without chemotherapy is associated with an excellent outcome
por: Boyles, Glenn P., et al.
Publicado: (2019)

Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
por: Ball, Graeme, et al.
Publicado: (2017)

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
por: Krasner, C N, et al.
Publicado: (2007)

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
por: Nagao, Shoji, et al.
Publicado: (2020)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients
por: ZHAO, MIN, et al.
Publicado: (2014)

Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
por: Chen, Chen, et al.
Publicado: (2020)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
por: Guerra Alía, Eva María, et al.
Publicado: (2019)

Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies
por: Mantia-Smaldone, Gina M, et al.
Publicado: (2010)

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer
por: Dijkgraaf, Eveline M., et al.
Publicado: (2015)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma
por: Ak, Guntulu, et al.
Publicado: (2015)

Gemcitabine in Recurrent Meningioma
por: Khaddar, Satvik, et al.
Publicado: (2020)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety
por: Oaknin, Ana, et al.
Publicado: (2021)

A Regimen of Taxol, Ifosfamide, and Platinum for Recurrent Advanced Squamous Cell Cancer of the Anal Canal
por: Golub, Diana V., et al.
Publicado: (2011)

Interest to consider re-challenging by cetuximab and platinum containing regimen in recurrent Head and Neck Cancer
por: Borel, Christian, et al.
Publicado: (2018)

Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study
por: Imai, Hiroo, et al.
Publicado: (2019)

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
por: Salimon, Maëva, et al.
Publicado: (2018)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer
por: Flynn, Michael J., et al.
Publicado: (2022)

Overcoming the challenges of drug development in platinum-resistant ovarian cancer
por: Eskander, Ramez N., et al.
Publicado: (2023)

Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
por: Kase, Adam M., et al.
Publicado: (2023)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
por: Cui, Qingli, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib Combined with Etoposide in Patients with Recurrent Platinum-resistant Epithelial Ovarian Cancer: A Retrospective Study
por: Huang, Qi, et al.
Publicado: (2020)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study
por: Kim, Mi-Jung, et al.
Publicado: (2008)

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
por: Tate, Shinichi, et al.
Publicado: (2020)

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)
por: Hamanishi, Junzo, et al.
Publicado: (2021)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer
por: López-Guerrero, José Antonio, et al.
Publicado: (2015)

Cancer Stem Cell Assay for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer
por: Howard, Candace M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bc6acq3tbpmdsn919k7igplv99